Status:
UNKNOWN
Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
Lead Sponsor:
Shandong University
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess and compare the effectiveness of levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple regimens for the primary treatment of Hel...
Detailed Description
Helicobacter pylori(H.pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Stron...
Eligibility Criteria
Inclusion
- Patients aged 18-70 with H. pylori infection.
- Patients Allergic to Penicillin.
Exclusion
- Patients with previous H. pylori eradication therapy.
- Patients treated with Histamine-receptor antagonist, proton pump inhibitor, bismuth and antibiotics in the previous 4 weeks.
- Patients with gastrectomy, acute gastrointestinal bleeding and advanced gastric cancer.
- Patients with known or suspected allergy to study medications.
- Currently pregnant or lactating.
- Inability to provide informed consent
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04122287
Start Date
November 1 2019
End Date
December 1 2022
Last Update
November 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital
Jinan, Shandong, China, 250000